Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Does COVID-19 affect cancer patients receiving immunotherapy more severely?

Does COVID-19 affect cancer patients receiving immunotherapy more severely?

Cancer patients are known to face a risk of more severe COVID-19, the illness caused by the novel coronavirus and a higher risk of death. However, until now there has been no guidance on how certain cancer treatments, such as immunotherapies, affect these risks.

Some concerns had been raised about the effects of immune checkpoint inhibitors, the most commonly used type of immunotherapy in recent years, on COVID-19 treatment. However, a new study published on 12 May found that, in patients with lung cancer, immunotherapy that blocks PD-1 and activates the immune system against cancer did not affect the course of COVID-19. The study included 69 patients receiving outpatient treatment for lung cancer who were diagnosed with COVID-19 in March and April.

We generally do not think that immune checkpoint inhibitors suppress the immune system and make patients more susceptible to infections. However, oncology professionals had wondered about some side effects that cancer patients receiving immunotherapy might develop and whether these could affect their ability to fight infections such as coronavirus. We can say that this study has reduced our concerns.

One hypothesis proposed to explain the situation is that the medicines might trigger the excessive immune response observed in some patients and lead to severe illness.

The discovery of immune checkpoint inhibitors and their benefits in treatment have been revolutionary. Metastatic lung cancers are among the conditions in which they produce favorable results, providing a 20-25% survival or longer-life benefit; in other words, one in every 5 patients with advanced lung cancer lives for more than 5 years with immunotherapy. However, cytokine release syndrome, often observed in hospitalized patients with severe COVID-19, can also occur with treatments using immune checkpoint inhibitors. The similarities between these two situations are concerning. Conditions that impair lung function can have very serious consequences.

The study analyzed patients grouped according to whether they had received their most recent immunotherapy dose within 6 months or within 6 weeks, or their first dose within the first 3 months. No difference in COVID-19 severity was observed between the groups.

However, the small number of participants should also be emphasized. There may be many differences in their treatment histories and in the treatments they received for coronavirus. In this situation, it is very difficult to reach a firm conclusion without a homogeneous study group. Other factors alongside lung cancer, such as heart disease, diabetes, high blood pressure and smoking, are also known to increase the risk of death in patients with both lung cancer and COVID-19.

Reports from China show a higher mortality rate among cancer patients diagnosed with COVID-19 (5.6%) than the overall mortality rate (3%). A similar pattern is seen in people with diabetes (7.3%) and chronic respiratory disease (6.3%). These COVID-19 rates are concerning for people with additional illnesses. We know that our patients have weaker immune systems. Therefore, cancer patients with lung cancer who are diagnosed with COVID-19 should be hospitalized for monitoring.

Commentary - Summary

Although this was a small study with limitations, its findings addressed some uncertainties and indicated that using these treatments during the pandemic might not pose a problem. However, larger, more detailed studies are needed before firm conclusions can be drawn. Treatment using immune checkpoint inhibitors is not the only option used for cancer patients. Radiotherapy and targeted cancer medicines called tyrosine kinase inhibitors are also used and may cause lung problems. Therefore, many studies are being conducted to investigate the effects of different cancer treatments on COVID-19 severity and mortality.

- ALL OUR CORONAVIRUS ARTICLES -

Sources

Luo J, Rizvi H, Egger J, et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 12 May 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Does COVID-19 affect cancer patients receiving immunotherapy more severely?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy